Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISIONBLUE vs CARDRASE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Visionblue (trypan blue) is a dye that selectively stains the anterior lens capsule and vitreous, enhancing visualization during ophthalmic surgeries such as cataract extraction and vitrectomy. It does not exert pharmacological activity but acts as a vital stain.
CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Staining of the anterior lens capsule during cataract surgery or capsulorhexis,Staining of vitreous in vitrectomy procedures
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute gouty arthritis,Primary dysmenorrhea
0.5 m L of 0.025% solution intracameral injection (single use).
Adult: 100 mg orally twice daily.
Approximately 2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 12 hours).
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Visionblue is not metabolized; it is cleared from the eye via aqueous humor outflow and systemic absorption is negligible.
Hepatic metabolism primarily via CYP2C9, with minor contributions from CYP3A4 and CYP2C8. Metabolites are inactive and excreted renally.
Primarily eliminated unchanged via renal glomerular filtration; minimal biliary excretion (<5%).
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (10-20%); biliary/fecal elimination accounts for 10-15%.
Negligible (<5%), primarily to albumin.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.2 L/kg, reflecting confinement to extracellular fluid and minimal tissue binding.
0.2-0.3 L/kg, indicating limited distribution into tissues, consistent with high plasma protein binding.
Not applicable for systemic routes; intraocular administration yields direct local effect.
Oral bioavailability is 80-90% with modest first-pass metabolism; intravenous administration yields 100% bioavailability.
No dosage adjustment required; VISIONBLUE is not systemically absorbed.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: 100 mg once daily. GFR 15-29 m L/min: 50 mg once daily. GFR <15 m L/min: Not recommended.
No dosage adjustment required; VISIONBLUE is not systemically absorbed.
Child-Pugh A: No adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: Not recommended.
Safety and efficacy not established in pediatric patients; no standard dosing available.
Children ≥1 year: 2 mg/kg orally twice daily, up to a maximum of 100 mg/dose.
No specific adjustment; use adult dosing as indicated.
Initial dose of 50 mg once daily; may increase to 100 mg once daily based on tolerability.
None
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft surgery.
Intraocular use only; do not inject intravenously,Potential for corneal endothelial toxicity if excessive volume or prolonged contact,May cause transient increase in intraocular pressure,Hypersensitivity reactions have been reported,Use with caution in patients with compromised corneal endothelium
Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, anaphylactoid reactions, serious skin reactions, hematologic toxicity, hepatic impairment, asthma exacerbation, and use in pregnancy (avoid in later stages).
Known hypersensitivity to trypan blue or any component of the formulation,Intraocular use in patients with significant corneal endothelial compromise
Hypersensitivity to CARDRASE or any NSAID; history of asthma, urticaria, or allergic-type reactions after aspirin or NSAIDs; perioperative pain in CABG surgery; advanced renal disease; severe hepatic impairment; active peptic ulcer or GI bleeding; third trimester of pregnancy; patients with known sulfonamide allergy (if applicable).
No known food interactions. This drug is administered intraocularly and is not ingested; systemic absorption is negligible.
Avoid high-sodium foods to reduce fluid retention. Limit intake of potassium-rich foods if hyperkalemia is a risk. Grapefruit juice may increase drug levels; avoid concurrent use.
No teratogenic effects in animal studies; limited human data. Avoid use in pregnancy unless benefits outweigh risks.
First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third trimester: Risk of neonatal hypoglycemia, hypotonia, and respiratory depression with maternal use near term.
Minimal systemic absorption; M/P ratio not reported. Compatible with breastfeeding but avoid direct infant eye contact.
Limited data; drug is excreted in breast milk. M/P ratio unknown. Avoid breastfeeding during therapy due to potential adverse effects in the infant.
No dosage adjustment needed; pharmacokinetics unchanged in pregnancy.
Increased renal clearance during pregnancy may require 20-30% dose escalation in second and third trimesters. Monitor therapeutic drug levels to maintain efficacy. Consider dose reduction postpartum.
Vision Blue (trypan blue ophthalmic solution 0.06%) is a vital dye used as a surgical aid in cataract surgery for staining the anterior capsule during capsulorhexis. It selectively stains the anterior lens capsule due to its affinity for basement membranes, facilitating visualization in eyes with poor red reflex (e.g., white cataracts, dense brunescent cataracts). Avoid injecting into the vitreous; if encountered, perform anterior vitrectomy immediately. Use with caution in patients with pseudophakic or aphakic eyes due to risk of dye retention in the vitreous. Discard any unused solution after surgery; single-use vial only.
CARDRASE (carbonic anhydrase inhibitor) may cause metabolic acidosis; monitor serum bicarbonate. Contraindicated in cirrhosis due to risk of hepatic encephalopathy. Can cause hypokalemia; check electrolytes. Adjust dose in renal impairment (Cr Cl <30 m L/min).
This medication is used during eye surgery to help your surgeon see the lens capsule clearly.,It is not self-administered; it will be applied by your surgeon during the procedure.,Inform your surgeon about any allergies, especially to dyes or medications.,Report any eye pain, redness, or vision changes after surgery immediately.,You may experience temporary blue discoloration of the eye, which resolves within days.
Take with food to reduce gastrointestinal upset.,Drink plenty of fluids to prevent kidney stones.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report unexplained bruising or bleeding, as it may indicate thrombocytopenia.,Do not drive or operate machinery until you know how this medication affects you, as dizziness or drowsiness can occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VISIONBLUE vs CARDRASE, answered by our medical review team.
VISIONBLUE is a Ophthalmic Dye/Stain that works by Visionblue (trypan blue) is a dye that selectively stains the anterior lens capsule and vitreous, enhancing visualization during ophthalmic surgeries such as cataract extraction and vitrectomy. It does not exert pharmacological activity but acts as a vital stain.. CARDRASE is a Antiarrhythmic Agent that works by CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VISIONBLUE and CARDRASE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VISIONBLUE is: 0.5 m L of 0.025% solution intracameral injection (single use).. The standard adult dose of CARDRASE is: Adult: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VISIONBLUE and CARDRASE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VISIONBLUE is classified as Category C. No teratogenic effects in animal studies; limited human data. Avoid use in pregnancy unless benefits outweigh risks.. CARDRASE is classified as Category C. First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.